Discriminating dyslipidemias - a South African perspective

Abstract

Clinical observation and scientific research have established that premature atherosclerotic vascular disease is strongly associated with markedly elevated low-density lipoprotein (LDL) cholesterol levels. Genetic disorders that impair LDL clearance via LDL receptors (LDLRs) are classified into heterozygous and homozygous familial hypercholesterolemia (FH) phenotypes. The heterozygous FH phenotype is characterized by LDL cholesterol levels exceeding 4.9 mmol/L, the presence of tendon xanthomas, and premature heart disease. In contrast, homozygous FH is characterized by LDL cholesterol levels above 13 mmol/L, both cutaneous and tendon xanthomas, and may lead to atherosclerotic vascular disease manifesting in childhood. FH is relatively common and occurs at even higher frequencies in populations founded by small ancestral groups, as documented in South Africa through investigations conducted in tertiary healthcare settings. Despite significant advances in the diagnosis and treatment of lipid and lipoprotein disorders, many of which are part of the differential diagnosis of FH, support for the diagnosis and management of FH has declined. While existing clinical guidelines address most cases of hypercholesterolemia, a subset of individuals with severe dyslipidemias requires more specialized evaluation. Referral criteria are proposed to help identify these patients. Given the high cardiovascular risk associated with severe hypercholesterolemia and the availability of effective treatments, there is an urgent need to strengthen, coordinate, and integrate clinical and laboratory services in South Africa to differentiate among the various causes of these disorders.

Keywords

Hypercholesterolemia / familial hypercholesterolemia / phytosterolemia / xanthomas

References

[1] Ose L.Müller-harbitz disease--familial hypercholesterolemia.Tidsskr Nor Laegeforen2002;122:924-5

[2] Brown MS.A receptor-mediated pathway for cholesterol homeostasis.Science1986;232:34-47

[3] Taranto MD, Fortunato G. Genetic heterogeneity of familial hypercholesterolemia: repercussions for molecular diagnosis.Int J Mol Sci2023;24:3224 PMCID:PMC9961636

[4] Thompson GR,Marais AD,Pilcher GJ.Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol.Eur Heart J2018;39:1162-8

[5] Blom DJ,Jones S.Non-denaturing polyacrylamide gradient gel electrophoresis for the diagnosis of dysbetalipoproteinemia.J Lipid Res2003;44:212-7

[6] Phatlhane DV.Severe hypercholesterolemia mediated by lipoprotein X in a patient with cholestasis.Ann Hepatol2015;14:924-8

[7] Slack J.Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states.Lancet1969;2:1380-2

[8] Firth JC.Familial hypercholesterolaemia: the Cape Town experience.S Afr Med J2008;98:99-104

[9] Talmud PJ,Whittall R.Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study.Lancet2013;381:1293-301

[10] Minchiotti L,Campagnoli M,Galliano M.Diagnosis, phenotype, and molecular genetics of congenital Analbuminemia.Front Genet2019;10:336 PMCID:PMC6478806

[11] Bashir A,Duseja A.Enzyme replacement therapy in lysosomal acid lipase deficiency (LAL-D): a systematic literature review.Ther Adv Rare Dis2021;2:26330040211026928 PMCID:PMC10032452

[12] D’Erasmo L,Arca M.Autosomal recessive hypercholesterolemia: update for 2020.Curr Opin Lipidol2020;31:56-61

[13] Windler E,Berthold HK.Phytosterols and cardiovascular risk evaluated against the background of phytosterolemia cases-a German expert panel statement.Nutrients2023;15:828 PMCID:PMC9963617

[14] Fellin R.Lipoprotein-X fifty years after its original discovery.Nutr Metab Cardiovasc Dis2019;29:4-8

[15] Stelten BML,Marais AD.Cerebrotendinous xanthomatosis without neurological involvement.J Intern Med2021;290:1039-47

[16] Marais AD.Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease.Pathology2019;51:165-76

[17] Wilemon KA,Aguilar-Salinas C.Reducing the clinical and public health burden of familial hypercholesterolemia: a global call to action.JAMA Cardiol2020;5:217-29

[18] Barnard CN.The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town.S Afr Med J1967;41:1271-4

[19] Seftel HC,Sandler MP.A host of hypercholesterolaemic homozygotes in South Africa.Br Med J1980;281:633-6 PMCID:PMC1714090

[20] Gevers W.Three mutations that cause familial hypercholesterolemia in Afrikaners identified-a milestone in South African medicine.S Afr Med J1989;76:393-4

[21] Marais AD,Rose AG.Fatal outcome of homozygous familial hypercholesterolaemia in a black patient. A case report.S Afr Med J1990;77:588-90

[22] Marais AD.A diversity of genetic hyperlipoproteinaemias in black patients. Experience at the lipid clinics at Groote Schuur hospital and red cross war memorial children's hospital, Cape Town.S Afr Med J1986;70:583-7

[23] Langenhoven E,Thiart R.Two novel point mutations causing receptor-negative familial hypercholesterolemia in a South African Indian homozygote.Atherosclerosis1996;125:111-9

[24] Marais AD,Firth JC,Neuwirth CKY.Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia.J Lipid Res1997;38:2071-8

[25] Davey Smith G.Should there be a moratorium on the use of cholesterol lowering drugs?.BMJ1992;304:431-4 PMCID:PMC1881265

[26] Marais AD.Planning rational management of chronic diseases-lessons from a lipid clinic.S Afr Med J1995;85:340-1

[27] Marais AD.Lipidology: adding value to tertiary services.S Afr Med J2008;98:91-2

[28] Mach F,Catapano AL.2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.Eur Heart J2020;41:111-88

[29] Klug EQ,Marais AD.South African dyslipidaemia guideline consensus statement: 2018 update A joint statement from the South African Heart Association (SA Heart) and the Lipid and Atherosclerosis Society of Southern Africa (LASSA).S Afr Med J2018;108:973-1000.

[30] Klug QE.Heart groups in South Africa advocate for tighter LDL-C control and lipoprotein(a) testing to curb atherosclerotic cardiovascular disease.S Afr Med J2024;114:e1973

[31] Marais AD.Discovering hypertriglyceridaemia.S Afr Med J2021;111:13363

[32] Marais AD,Raal FJ.Response to: prescribed minimum benefits complaints: a 5-year retrospective review.S Afr Med J2024;114:e2450

[33] Marais AD,Raal FJ.Management of hyperlipidaemia.S Afr Med J2024;114:e1016

[34] Marais AD,Raal FJ.On Behalf Of The Lipid And The Lipid And Atherosclerosis Society Of Southern AfricaFamilial hypercholesterolaemia in South Africa: a reminder.S Afr Med J2021;111:700-1

[35] South African Government. National Health Laboratory Service Act 37 of 2000. Republic of South Africa. Available from:https://www.gov.za/documents/national-health-laboratory-service-act [Last accessed on 18 JuL 2025]

[36] Marais AD. Familial hypercholesterolaemia and genetic dyslipidaemia: opportunities and needs in management as seen from South Africa. Data presented at the ISA 2012 Satellite Meeting of the International Atherosclerosis Society, Sydney, Australia. 2012.

[37] Marais AD.Severe hypercholesterolaemia with a high risk of atherosclerosis may be precipitated by a high-sterol diet.S Afr Med J2018;108:12406